BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31519612)

  • 1. Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer.
    Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
    Anticancer Res; 2019 Sep; 39(9):5039-5045. PubMed ID: 31519612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.
    Nishioka Y; Moriyama J; Matoba S; Kuroyanagi H; Hashimoto M; Shindoh J
    Dig Surg; 2018; 35(3):187-195. PubMed ID: 28848205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy.
    Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Matsutani S; Wang EN; Maeda K; Hirakawa K; Ohira M
    Anticancer Res; 2019 Feb; 39(2):1051-1057. PubMed ID: 30711994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting early intrahepatic recurrence after curative resection of colorectal liver metastases with molecular markers.
    Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Yamamoto T; Addeo P; Jaeck D; Bachellier P
    World J Surg; 2015 May; 39(5):1167-76. PubMed ID: 25561185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
    Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
    Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
    Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
    Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is complete liver resection without resection of synchronous lung metastases justified?
    Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
    Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
    Devaud N; Kanji ZS; Dhani N; Grant RC; Shoushtari H; Serrano PE; Nanji S; Greig PD; McGilvray I; Moulton CA; Wei A; Gallinger S; Cleary SP
    HPB (Oxford); 2014 May; 16(5):475-80. PubMed ID: 23927606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
    Pietrantonio F; Di Bartolomeo M; Cotsoglou C; Mennitto A; Berenato R; Morano F; Coppa J; Perrone F; Iacovelli R; Milione M; Alessi A; Vaiani M; Bossi I; Ricchini F; Scotti M; Caporale M; Bajetta E; de Braud F; Mazzaferro V
    Clin Colorectal Cancer; 2017 Sep; 16(3):e191-e198. PubMed ID: 27979717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection.
    Deng Y; Zhao Y; Qin J; Huang X; Wu R; Zhou C; Pan Z
    Pathol Oncol Res; 2021; 27():633480. PubMed ID: 34257601
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer.
    Peng J; Zhang R; Zhao Y; Wu X; Chen G; Wan D; Lu Z; Pan Z
    Chin J Cancer; 2017 Dec; 36(1):96. PubMed ID: 29268783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?
    Pan Z; Peng J; Lin J; Chen G; Wu X; Lu Z; Deng Y; Zhao Y; Sui Q; Wan D
    Cancer Commun (Lond); 2018 May; 38(1):29. PubMed ID: 29843800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases.
    Yamashita S; Shindoh J; Mizuno T; Chun YS; Conrad C; Aloia TA; Vauthey JN
    J Hepatol; 2017 Jul; 67(1):56-64. PubMed ID: 28192187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
    Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases.
    Kokudo N; Seki M; Ohta H; Azekura K; Ueno M; Sato T; Moroguchi A; Matsubara T; Takahashi T; Nakajima T; Aiba K
    Ann Surg Oncol; 1998 Dec; 5(8):706-12. PubMed ID: 9869517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.